552331-57-4

Basic information

• Product Name: Pyridine, 4-ethenyl-2-fluoro- (9CI)
• Synonyms: Pyridine, 4-ethenyl-2-fluoro- (9CI);2-fluoro-4-vinylpyridine;4-ethenyl-2-fluoroPyridine
• CAS NO: 552331-57-4
• Molecular Formula: C₇H₆FN
• Molecular Weight: 123.1276432
• Product Categories: PYRIDINE
• Mol File: 552331-57-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 180.217 °C at 760 mmHg
• Flash Point: 62.793 °C
• Appearance: /
• Density: 1.158 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.31±0.10(Predicted)
• CAS DataBase Reference: Pyridine, 4-ethenyl-2-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 4-ethenyl-2-fluoro- (9CI)(552331-57-4)
• EPA Substance Registry System: Pyridine, 4-ethenyl-2-fluoro- (9CI)(552331-57-4)

Safety Data

• Hazardous Substances Data: 552331-57-4(Hazardous Substances Data)

Usage

General Description

Pyridine, 4-ethenyl-2-fluoro- (9CI) is a chemical compound with the molecular formula C8H6FN. It is a derivative of pyridine with a fluoro and ethenyl substituent at the 2 and 4 positions, respectively. This chemical is used in various organic synthesis processes and as a reagent in pharmaceutical and agrochemical industries. It has properties that make it useful in the production of pharmaceutical drugs and can also be used as an intermediate in the synthesis of other chemical compounds. Additionally, it is known to have potential applications in materials science and nanotechnology. However, it is important to handle this chemical with care as it may have hazardous properties and should be used in accordance with proper safety measures and guidelines.

Upstream product

• 372-48-5 2-fluoropyridine 
• 128071-98-7 4-bromo-2-fluoropyridine 
• 75927-49-0 pinacol vinylboronate 
• 1176209-54-3 2-(2-fluoropyridin-4-yl)ethyl methylsulfonate 
• 697216-36-7 N₁-ethyl-N₂-phthalyl-1,2-ethanediamine 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 22282-70-8 2-fluoro-4-iodopyridine 
• 1000562-43-5 2-fluoro-4-(2-hydroxyethyl)pyridine 
• 461-87-0 2-fluoro-4-methylpyridine 

Downstream Products

• 1430235-19-0 C₁₉H₁₈FNSi 
• 1430235-43-0 C₁₉H₁₆FNSi 
• 882170-48-1 [1-{5-[2-(2-benzylamino-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester 
• 882170-43-6 [1-{5-[2-(2-benzylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-2-(1H-indol-3-yl)-ethyl]-carbamic acid tert-butyl ester 
• 882170-42-5 (2-(1H-indol-3-yl)-1-{5-[2-(2-phenylsulfanyl-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-ethyl)-carbamic acid tert-butyl ester 
• 882170-41-4 (2-(1H-indol-3-yl)-1-{5-[2-(2-phenoxy-pyridin-4-yl)-vinyl]-pyridin-3-yloxymethyl}-ethyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Fe-Catalyzed Reductive Couplings of Terminal (Hetero)Aryl Alkenes and Alkyl Halides under Aqueous Micellar Conditions

The combination of a vinyl-substituted aromatic or heteroaromatic and an alkyl bromide or iodide leads, in the presence of Zn and a catalytic amount of an Fe(II) salt, to a net reductive coupling. The new C-C bond is regiospecifically formed at rt at the β-site of the alkene. The coupling only occurs in an aqueous micellar medium, where a radical process is likely, supported by several control experiments. A mechanism based on these data is proposed.

Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors

The present invention relates to the compound of formula (I): in which R1 represents a hydrogen atom, an optionally labelled halogen atom, a radionuclide or a Sn[(C1-C4)alkyl]3 group, Ar represents an aryl group

5-Substituted Derivatives of 6-Halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-Halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with Low Picomolar Affinity for α4β2 Nicotinic Acetylcholine Receptor and Wide Range of Lipophilicity: Potential Probes for Imaging with Positron Emission Tomography

Potential positron emission tomography (PET) ligands with low picomolar affinity at the nicotinic acetylcholine receptor (nAChR) and with lipophilicity (log D) ranging from - 1.6 to +1.5 have been synthesized. Most members of the series, which are derivatives of 5-substituted-6-halogeno-A-85380, exhibited a higher binding affinity at α4β2-nAChRs than epibatidine. An analysis, by molecular modeling, revealed an important role of the orientation of the additional heterocyclic ring on the binding affinity of the ligands with nAChRs. The existing nicotinic pharmacophore models do not accommodate this finding. Two compounds of the series, 6-[18F]fluoro-5-(pyridin-3-yl)-A-85380 ([18F]31) and 6-chloro-3-((2-(S)-azetidinyl)methoxy)-5-(2-[ 18F]fluoropyridin-5-yl)pyridine) ([18F]35), were radiolabeled with 18F. Comparison of PET data for [18F]31 and 2-[18F]FA shows the influence of lipophilicity on the binding potential. Our recent PET studies with [18F]35 demonstrated that its binding potential values in Rhesus monkey brain were ca. 2.5 times those of 2-[18F]FA. Therefore, [18F]35 and several other members of the series, when radiolabeled, will be suitable for quantitative imaging of extrathalamic nAChRs.